Allergy Therapeutics stock analysis
Allergy Therapeutics (AGYTF) Stock Price & Analysis
AGYTF Stock Chart & Stats
- Day’s Range
- $0.14 - $0.14
- 52-Week Range
- $0.11 - $0.15
- Previous Close
- $0.14
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $117.06M
- Enterprise Value
- $478.24M
- Total Cash (Recent Filing)
- $24.20M
- Total Debt (Recent Filing)
- $67.00M
- Price to Earnings (P/E)
- ―
- Beta
- -2.03
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Underlying-cause Allergy Treatments
A focus on allergy immunotherapy and diagnosis addresses the underlying disease rather than providing only symptom relief. That positioning can support differentiated products, recurring clinical demand, and a clearer specialty-pharmaceutical role over the next several quarters.
Revenue Resilience
Revenue resilience provides evidence that the company retains demand for its products despite severe profitability pressure. The 2026 rebound is modest, but maintaining the top line can preserve commercial scale and provide a base for future operational improvement.
Cash-loss Alignment
Cash outflow being broadly aligned with reported losses gives a clearer view of the company’s underlying economics than results heavily distorted by non-cash charges. This does not remove funding risk, but it makes performance and required operational improvements more transparent.
Bears Say
Severe Profitability Deterioration
The sharp gross-margin compression and very deep net losses indicate that revenue is currently converting into substantially weaker earnings than in 2021. Unless margins recover, the company will struggle to fund growth internally and may remain dependent on external capital.
Persistent Cash Burn
Repeated negative operating and free cash flow shows that the business has not yet reached self-sustaining cash generation. Continued annual cash consumption can reduce strategic flexibility, increase reliance on financing, and make recovery more sensitive to execution and funding conditions.
Negative Equity And Rising Debt
Negative equity combined with a large increase in debt signals substantial balance-sheet strain and limited financial flexibility. Higher leverage can constrain investment choices, increase dependence on continued funding, and leave the company less able to absorb further losses.
Allergy Therapeutics News
Allergy Therapeutics Deepens Real-World Data on Grassmuno® With New GRASS Study
Allergy Therapeutics ($GB:AGY) announced an update on their ongoing clinical study. The GRASS (Grass MATA MPL Real-world Assessment Study) is a prospective, open, multi-center observational study run by Allergy Therapeutics
AGYTF FAQ
What was Allergy Therapeutics’s price range in the past 12 months?
What is Allergy Therapeutics’s market cap?
When is Allergy Therapeutics’s upcoming earnings report date?
How were Allergy Therapeutics’s earnings last quarter?
Is Allergy Therapeutics overvalued?
Does Allergy Therapeutics pay dividends?
What is Allergy Therapeutics’s EPS estimate?
How many shares outstanding does Allergy Therapeutics have?
What happened to Allergy Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Allergy Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Allergy Therapeutics Stock Smart Score
Company Description
Allergy Therapeutics
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Manuel Llobet
- Employees
- 584
- Website
- www.allergytherapeutics.com
- Address
- Dominion Way, Worthing, WS, BN14 8SA, GB
Allergy Therapeutics (AGYTF) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 1 | 12 |
| Technical Analysis | 3 | 1 | 2 |
| Moving Averages | 2 | 0 | 10 |








